EMA explains how to develop modified-release drug formulations
This article was originally published in SRA
Executive Summary
The European Medicines Agency has agreed a new guideline on the development of modified-release (MR) dosage forms, describing the studies that will be needed to demonstrate the efficacy, safety and pharmacokinetic (PK) properties of formulations such as prolonged, delayed and multiphasic-release formulations of medicines1.